This Annex applies for devices intended for detection or quantification of markers of Trypanosoma cruzi (T. cruzi) infection.
Table 1 applies to first-line assays for antibodies against T. cruzi (anti-T. cruzi).
Table 2 applies to confirmatory and supplemental anti-T. cruzi assays.
Table 3 applies to qualitative and quantitative NAT devices for T. cruzi DNA.
[Blood donor populations shall be investigated from at least two blood donation centres and consist of consecutive blood donations, which have not been selected to exclude first-time donors.]
Performance characteristic | Specimens | Specimen number, features, use | Acceptance criteria
Diagnostic sensitivity | Positive specimens |
≥400 positive specimens, including highly positive confirmed by at least two different serological tests for different antibodies to T.cruzi.
Of those 400, ≥25 parasite positive specimens which have been confirmed by direct detection.
99.5% overall sensitivity
Seroconversion panels | To be defined when available | Diagnostic sensitivity during seroconversion shall represent the state of the art
Analytical sensitivity | Standards |
WHO international standards
NIBSC code: 09/186
NIBSC code: 09/188
Diagnostic specificity | Unselected donors (including first-time donors) | ≥5000 | ≥99,5%
Hospitalised patients | ≥200 | Potential limitations for specificity, if any, shall be identified
Cross-reactivity | Potentially cross-reacting specimens |
≥100 in total
including the following specimens: positive for anti-Toxoplasma gondii; at least 5 specimens positive for anti-Leishmania; RF+; related microbial agents or other infectious agents; SLE patients; antiphospholipid antibody positive patients; pregnant women, etc.
Performance characteristic | Specimens | Specimen number, features, use | Acceptance criteria
Diagnostic sensitivity | Positive specimens |
≥300 positive specimens, including highly positive confirmed by at least two different serological tests for different antibodies to T.cruzi.
Of those 300, ≥25 parasite positive specimens, which have been confirmed by direct detection.
≥99% identification as “confirmed positive” or “indeterminate”
Seroconversion panels | As available | Diagnostic sensitivity during seroconversion shall represent the state of the art, if applicable
Analytical sensitivity | Standards |
WHO international standards
NIBSC code: 09/186
NIBSC code: 09/188
Diagnostic specificity | Negative specimens | ≥200 | ≥99%
Clinical specimens | ≥200 | Potential limitations for specificity, if any, shall be identified
Cross-reactivity | Potentially cross-reacting specimens | ≥50 in total, including specimens from pregnant women and specimens with indeterminate results in other confirmatory assays
For target sequence amplification devices, a functionality control for each specimen (internal control) shall reflect the state of the art. This control shall as far as possible be used throughout the whole process, i.e. extraction, amplification/hybridisation, detection.
Genotype and/or subtype detection shall be demonstrated by appropriate primer or probe design validation and shall also be validated by testing characterised genotyped specimens.
Potential cross-reactivity of non-target nucleic acid sequences shall be analysed by appropriate primer or probe design validation and shall also be validated by testing selected specimens.
Results of quantitative NAT devices shall be traceable to international standards or calibrated reference materials, if available, and be expressed in international units utilised in the specific field of application.
[Reference: European Pharmacopeia 9.0, 2.6.21 Nucleic acid amplification techniques, Validation.]
Performance characteristic | Specimens | Specimen number, features, use | Acceptance criteria
Analytical sensitivity | Characterized in-house reference preparation (as long as international reference materials are not available) |
NAT sensitivity and NAT LOD shall be validated by dilution series of reference materials, testing of replicates (minimal 24) at different analyte concentrations, including those with transition from positive to negative results with the respective NAT device.
LOD shall be expressed as 95% positive cut-off value (IU/ml) after statistical analysis (e.g. Probit).
According to the state of the art
Diagnostic sensitivity: different T.cruzi strains / isolates | Patient specimens from different regions determined as T.cruzi DNA positive by comparator device; sequence variants |
≥100
Dilution series of T.cruzi positive cell cultures (isolates) or T.cruzi positive materials from animal models may serve as potential substitutes
According to the state of the art
Diagnostic specificity | Negative specimens | ≥100 | According to the state of the art
Cross-reactivity | Potentially cross-reacting specimens | ≥10 human specimens positive for other parasites, e.g. Plasmodium species, Trypanosoma brucei. Positive cell cultures may serve as potential substitutes | According to the state of the art
Carry-over | | At least five runs with alternating high-positive and negative specimens shall be performed during robustness studies. The T.cruzi titres of the high positive specimens shall be representative of high T.cruzi titres occurring naturally. | According to the state of the art
Whole system failure rate | | ≥100 T.cruzi DNA low-positive specimens shall be tested. These specimens shall contain a T.cruzi concentration equivalent to three times the 95 % positive cut-off T.cruzi concentration. | ≥99% positive